Clinical Trials Delivering New Optimism in Fight Against Triple-Negative Breast Cancer

It’s been a year and a half since the US Food and Drug Administration approved the first targeted immunotherapy in the treatment of triple-negative breast cancer (TNBC) leading the way to what’s been hailed as a “new clinical paradigm”. This year has continued to deliver new optimism in the fight […]

It’s been a year and a half since the US Food and Drug Administration approved the first targeted immunotherapy in the treatment of triple-negative breast cancer (TNBC) leading the way to what’s been hailed as a “new clinical paradigm”. This year has continued to deliver new optimism in the fight against TNBC, as new clinical trials are being prepared and launched by pharma developers including the work of Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), ERYTECH Pharma S.A. (NASDAQ:ERYP), Oncocyte Corporation (NYSE:OCX), and AstraZeneca PLC (NYSE:AZN).

Most recently a new study was kicked off at the Rutgers Cancer Institute of New Jersey and the Ohio State University Comprehensive Cancer Center, through a collaboration between Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and Incyte Corporation (NASDAQ:INCY).

Oncolytics Biotech announced the dosing of the first patient, in what’s been dubbed the IRENE Study, it is a single-arm, open-label, phase 2 study involving 25 enrolled patients, evaluating the combination of the company’s flagship asset pelareorep and Incyte’s retifanlimab for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer.

“The paucity of treatment options in metastatic triple-negative breast cancer combined with its aggressive clinical behavior results in a poorer prognosis when compared to other subtypes of breast cancer,” said Dr. Mridula George, M.D., Medical Oncologist, Rutgers Cancer Institute of New Jersey and Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School and Principal Investigator in the IRENE study. “This is an exciting study to evaluate the role of immunomodulation in the tumor microenvironment as a treatment option. I’m looking forward to getting this study underway to potentially make an impact in the lives of patients affected with metastatic triple-negative breast cancer.”

Dr. Mridula has expressed their research team’s targets evaluate induced adaptive responses of pelareorep that interacts with inhibition of PD-1 in patients suffering from TNBC.

IRENE is an extension of Oncolytics’ lead breast cancer program into TNBC, a subtype of the new disease. The main endpoints of the study are safety and objective response. In the secondary endpoint, the research teams will study the overall survival and progression-free survival of the patients.

Oncolytics’ pelareorep has already shown that it can generate autoreactive T cells, which can boost the efficacy of anti-PD-1 agents, which is why it’s being tested in combination with retifanlimab. Essentially pelareorep unregulates PD-L1 expression in the tumors. This prior clinical data shows pelareorep has the potential to address a pressing unmet need in challenging TNBC indications.

In another combination study, the Canadian Cancer Trials Group recently launched a Phase 2 study of a combination of Imfinzi from AstraZeneca PLC (NYSE:AZN) with an investigational compound that stops cell division by inhibiting a protein called polo-life kinase 4.

Both AstraZeneca’s Imfinzi and Oncolytics Biotech’s pelareorep are a type of immunotherapy called an immune checkpoint inhibitor that prevents a protein called PD-L1 from interacting with the PD-1 receptor in immune cells. Cancer cells often use this interaction to evade immune attacks.

“Immunotherapy in combination with chemotherapy has shown promise in [TNBC]; however, non-chemotherapy combinations which avoid those toxicities and may have activity in the chemorefractory setting are of particular interest,” said David Cescon, MD, medical oncologist at Princess Margaret Cancer Centre.

According to a recent release from Oncocyte Corporation (NYSE:OCX), there are close to 3,000 ongoing immune-therapy clinical trials in the US alone, and up to 750,000 patients who may be eligible for immunotherapy treatment each year.

Through the sharing of peer-reviewed research, Oncocyte demonstrated the utility of its TNBCType-IM assay to identify the most suitable cell lines to help biopharma and academic researchers develop new TNBC treatments. Published research demonstrates the test’s ability to work consistently both in vitro and in vivo in six cell lines used in drug development, suggesting promise in research applications.

Another novel drug candidate, eryaspase, is being evaluated to target cancer cells’ altered amino acid metabolism, primarily in metastatic pancreatic, but also in TNBC.

Eryaspase’s developers, ERYTECH Pharma S.A. (NASDAQ:ERYP) are currently aiming to enroll 64 patients in its phase 2 of a trial for its lead asset to treat TNBC. For this indication, eryaspase in combination with gemcitabine and carboplatin chemotherapy, compared to chemotherapy alone, in the first-line setting is being evaluated in the ongoing phase 2/3 TRYbeCA2 trial among patients with metastatic TNBC.

Since the FDA’s March 2019 accelerated approval of the combination of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) for the frontline treatment of patients with unresectable locally advanced or metastatic PD-L1–positive TNBC, there has clearly been plenty of optimism and targeted improvements.

“It is a really exciting time in breast cancer,” said Hope S. Rugo, MD, professor in the Department of Medicine and director of Breast Oncology and Clinical Trials Education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center in an interview with Oncology Nursing News. “We’ve seen so many advances in the [immuno-oncology arena] in a disease where we haven’t had good treatment options.”

Article Source:

USA News Group

[email protected]


Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Source link


Next Post

Sunak announces fresh financial rescue package for businesses hit by Covid lockdowns

Thu Oct 22 , 2020
Rishi Sunak has increased help for workers and businesses hit by Covid lockdowns in a financial rescue package issued less than a month after his last bailout. It includes more wage support for businesses struggling to keep employees on full time, more generous help for the self-employed and further cash […]